Drug Trial Radar · NCT04971109
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
467
Actual
Start
Mar 29, 2022
Primary completion
May 12, 2023
Study completion May 12, 2023
Sponsor
- Lead sponsor
- SIGA TechnologiesIndustry
- Sponsor type
- Industry
- Collaborators
- United States Department of Defense
- First posted
- Jul 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a study to assess the safety, tolerability, and PK of oral TPOXX 600 mg when administered twice daily (BID) for 28 days in adult subjects.
Conditions
- Smallpox
Interventions
TPOXXDrug
Study is based on Animal Regulatory Rule
TPOXX PlaceboOther
Does not apply
Primary outcomes
What the sponsor says the trial is designed to measure.
- CminTime frame: 28 days
- CmaxTime frame: 28 days
- AUC(0-last) - Total Systemic TPOXX ExposureTime frame: 28 days
- Time To Maximum TPOXX ExposureTime frame: 28 days
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Clinical Pharmacology of Miami, LLC
Miami, Florida
Advanced Pharma
Miami, Florida
Orlando Clinical Research Center
Orlando, Florida
Meridian Clinical Research
Omaha, Nebraska
Hassman Research Institute
Berlin, New Jersey
High Point Clinical Trials Center
High Point, North Carolina
Midwest Clinical Research Center
Dayton, Ohio
Coastal Carolina Research Center
North Charleston, South Carolina
PPD Phase I Clinic
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.